1. Institute of Public Health, Medical Decision Making, and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics, and Technology, Hall in Tirol, Austria;
2. Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria;
3. Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands;
4. Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris, France;
5. Department of Medicine, Division Hematology, University of Patras Medical School, Patras, Greece;
6. Groupe Francophone des Myélodysplasies (GFM), Paris, France;
7. Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden;
8. St James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom;
9. Department of Medicine A, Tel Aviv Sourasky (Ichilov) Medical Center and Sackler Medical Faculty, Tel Aviv University, Tel Aviv, Israel;
10. Hospital Universitario y Politécnico La Fe;
11. Instituto de Investigación Sanitaria La Fe, Valencia, Spain;
12. Department of Tumor Immunology, Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands;
13. Health Outcomes Research Unit, Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA), Rome, Italy;
14. Center for Health Decision Science, Department of Health Policy and Management, Harvard Chan School of Public Health, Boston, MA; and
15. Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA